Melanoma Study

Melanoma Study

About this study

Cancer immunotherapy has been shown to provide individuals with an excellent new type of treatment and is commonly used world-wide. 

Unfortunately, we know that not everyone will respond to their immunotherapy treatment in the same way. Currently, we are unable to determine whether or not an individual will have a positive response to immunotherapy treatment or not. Not to mention, the cost of this type of treatment is significant, both physcially and financially – with just one year of treatment costing approximately $150,000 AUD and only 30% of people with melanoma having any sort of response. 

Studies have shown that responses to immunotherapy may be affected by an individuals microbiome, known as the community of bacteria that live in our bowel. Depending on the conditions you have in your body, this group of bacteria can produce white cells known as T cells to fight infection or regulate the immune system. This is important because the effectiveness of cancer treatment depends on having the right balance of these T cells.

This study aims to analyse the bacteria in the gut, to find new biomarkers for immunotherapy in patients with melanoma. Identifying this biomarker will allow for rapid identification of individuals who will not respond to treatment, with the aim of overcoming immunotherapy resistance all together. 

What is involved?

We are looking for adults over the age of 18 who have been diagnosed with Stage IV melanoma and on their first line of immunotherapy for over 3 months.

This study will involve the collection of one:

  • Blood sample 
  • Faecal sample 
Participating in this study will help to improve treatment outcomes for individuals diagnosed with melanoma in the future.

If you would like to find out more about this study or register your interest, fill out the form below and our clinical trials team will be in touch shortly.

Dr Agnieszka Malczewski

Dr Agnieszka Malczewski

Lead Investigator

Dr Agnieszka Malczewski is a medical oncologist based at Icon Cancer Centre Brisbane. She works as a clinician at Icon Cancer Centre, and continues to complete her PhD focusing on ‘the microbiome-derived metabolome in cancer immunotherapy’. Her oncology interests include melanoma, cancer immunotherapy and upper gastrointestinal tract malignancies.

Delivery Partners:

Wesley Medical Research

Scroll to Top